Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Octopus Biosafety's Debt-to-Equity or its related term are showing as below:
STU:OCR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.71 Med: 0.46 Max: 344.5
Current: -0.83
During the past 10 years, the highest Debt-to-Equity Ratio of Octopus Biosafety was 344.50. The lowest was -2.71. And the median was 0.46.
STU:OCR's Debt-to-Equity is not ranked
in the Hardware industry.
Industry Median: 0.28
vs STU:OCR: -0.83
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Octopus Biosafety Debt-to-Equity Related Terms
Octopus Biosafety Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Octopus Biosafety's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OCR vs DELL, ANET, SNDK: Debt-to-Equity Comparison
For the Computer Hardware subindustry, Octopus Biosafety's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Octopus Biosafety Debt-to-Equity vs Hardware Industry
For the Hardware industry and Technology sector, Octopus Biosafety's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Octopus Biosafety's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Octopus Biosafety (STU:OCR) has a Debt-to-Equity of -0.83 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Octopus Biosafety and its competitors. According to the industry distribution chart, Octopus Biosafety ranks #999999 out of 2225 companies in the Hardware industry.
Is Octopus Biosafety's Debt-to-Equity too high?
Octopus Biosafety's current Debt-to-Equity is -0.83. Based on the distribution chart, Octopus Biosafety ranks #999999 out of 2225 companies in the Hardware industry, which is in the bottom quartile relative to peers. Overall, Octopus Biosafety has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Octopus Biosafety's Debt-to-Equity compare to DELL and ANET?
According to the Hardware industry distribution chart, Octopus Biosafety ranks #999999 out of 2225 companies for Debt-to-Equity. This places Octopus Biosafety in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Hardware company?
The median Debt-to-Equity among Hardware companies is 0.28, based on 2,225 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Octopus Biosafety and its competitors. For the Hardware industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Octopus Biosafety's current Debt-to-Equity is -0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Octopus Biosafety stock overvalued right now?
Octopus Biosafety (STU:OCR) has a current Debt-to-Equity of -0.83. The stock's GF Value™ is €0.08, compared to a current price of €0.15 — trading 83.8% above its estimated fair value. The current Debt-to-Equity is -0.83. Octopus Biosafety's overall GF Score™ is 7/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Octopus Biosafety (STU:OCR), the current Debt-to-Equity is -0.83 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Octopus Biosafety (STU:OCR) Overvalued in 2026?
Based on GuruFocus' analysis, Octopus Biosafety stock appears to be overvalued.
The current stock price of €0.15 is trading 83.8% above its estimated GF Value™ of €0.08.
Key valuation signals for STU:OCR:
Debt-to-Equity: -0.83
GF Value™: €0.08 vs. price of €0.15 (83.8% above fair value)
No single metric tells the full story. See the STU:OCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Octopus Biosafety is engaged in the design, manufacture and marketing of mobile, autonomous, intelligent and modular robots for use in Agro-food sector, Healthcare sector, Defense sector, Civil Protection sector, and Surveillance and Transport sector.
7GF Score
Get the complete analysis for STU:OCR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OCR has been successfully added to your 
